Form 4: Allogene Therapeutics Director Granted Significant Restricted Stock Unit Award

Allogene Therapeutics, Inc. Director Deborah M. Messemer was granted 95,400 Restricted Stock Units, vesting over one year, as disclosed in a recent SEC Form 4 filing.

Summary

• Deborah M. Messemer, a Director of Allogene Therapeutics, Inc. (ALLO), was granted 95,400 Restricted Stock Units (RSUs).
• The grant date for these RSUs is June 18, 2025.
• Each RSU represents a contingent right to receive one share of the company's Common Stock.
• The RSUs will vest in two equal semi-annual installments over a one-year period from the grant date, contingent on continued service through the vesting date.
• Ms. Messemer has elected to defer the receipt of Common Stock upon vesting pursuant to the Company's Non-Employee Director Compensation Policy until the earlier of (i) 30 days following separation from the Board or (ii) a change in control of the Company.

Sentiment

Score: 7

Explanation: The grant of Restricted Stock Units to a director is a positive step for corporate governance, aligning the director's interests with long-term shareholder value, and is a routine compensation practice.

Positives

• The grant of 95,400 Restricted Stock Units to a director aligns her interests with long-term shareholder value.
• The vesting schedule over one year encourages continued service and commitment from the director.

Risks

• The vesting of RSUs is subject to continued service, meaning the director must remain on the board for the units to fully vest.
• The ultimate value of the RSUs upon vesting is dependent on the future market price of Allogene Therapeutics, Inc. common stock.

Future Outlook

The Restricted Stock Units are set to vest in two equal semi-annual installments over a one-year period from the grant date of June 18, 2025, contingent on the director's continued service. Ms. Messemer has elected to defer the receipt of Common Stock upon vesting until 30 days after her separation from the Board or a change in control of the company.

Industry Context

This Form 4 filing is a standard disclosure of an insider equity award, common practice in the biotechnology and pharmaceutical industries to align executive and director incentives with shareholder interests and promote long-term commitment.

Comparison to Industry Standards

• The grant of Restricted Stock Units (RSUs) to a non-employee director is a common compensation practice across publicly traded companies, particularly in the biotechnology sector, to incentivize long-term commitment and align interests with shareholders.
• The specific number of units (95,400) and the vesting schedule (one year, semi-annual installments) are typical for such awards, comparable to similar grants observed at peer companies in the biopharmaceutical space, though the exact value depends on Allogene's market capitalization and compensation philosophy.

Corporate Governance

Stakeholder Impact

• Shareholders: The grant of RSUs to a director aligns their interests with shareholder value, as the director's compensation becomes tied to the company's stock performance.

Next Steps

• Continued service of Deborah M. Messemer on the Board of Directors for the RSUs to vest.
• Vesting of RSUs in two equal semi-annual installments over one year from June 18, 2025.
• Potential receipt of Common Stock by Ms. Messemer upon vesting, or deferral until separation from the Board or a change in control.

Key Dates

Keywords

Allogene Therapeutics, ALLO, SEC Form 4, Restricted Stock Units, RSU, insider transaction, director compensation, equity award